Now in its seventh year, the Inflammasome Therapeutics Summit stands as the only dedicated industry forum focused exclusively on drug development programs targeting the inflammasome multi-protein complex. The core goal is to evaluate this complex for therapeutic targeting, specifically focusing on connecting proof-of-concept biomarkers to meaningful disease endpoints and assessing the efficacy of combination therapies in the clinic. The event provides a crucial opportunity for attendees to share insights, benchmark progress across neuroinflammation, metabolic, and autoimmune indications, and dive deep into the latest clinical data, emerging mechanisms, and translational breakthroughs in the field.

The summit brings together over seventy experts, spanning from early discovery scientists to clinical strategists and drug developers. Participants are invited to connect with the leaders who are driving programs forward, tackle the most pressing translational challenges facing the field, and actively help chart the future direction of inflammasome therapeutics. By focusing on both the technological and clinical aspects, the summit equips attendees with the knowledge needed to innovate drug development and achieve clinical efficacy.